Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6425
    -0.0001 (-0.02%)
     

  • OIL

    82.90
    +0.17 (+0.21%)
     

  • GOLD

    2,398.20
    +0.20 (+0.01%)
     

  • Bitcoin AUD

    100,718.47
    +4,021.80 (+4.16%)
     

  • CMC Crypto 200

    1,330.94
    +18.32 (+1.40%)
     

  • AUD/EUR

    0.6018
    -0.0013 (-0.22%)
     

  • AUD/NZD

    1.0888
    +0.0013 (+0.12%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,327.18
    -67.14 (-0.39%)
     

  • FTSE

    7,828.89
    -48.16 (-0.61%)
     

  • Dow Jones

    37,913.68
    +138.30 (+0.37%)
     

  • DAX

    17,710.43
    -126.97 (-0.71%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

argenx to Present at Upcoming Investor Conferences

argenx SE
·1-min read
argenx SE
argenx SE


June 1, 2022

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in June:

  • Jefferies 2022 Global Healthcare Conference. Fireside chat on Wednesday, June 8, 2022 at 1:00 p.m. ET in New York, NY.

  • Goldman Sachs 43rd Annual Global Healthcare Conference. Fireside chat on Wednesday, June 15, 2022 at 3:20 p.m. PT in Rancho Palos Verdes, CA.

  • JMP Securities Life Sciences Conference. Management will participate in investor meetings on Wednesday, June 15, 2022 in New York, NY.

ADVERTISEMENT

Additional information regarding these events will be available on the Investors section of the argenx
website at argenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com